ArticleScientific reports2025
MBNL3 regulates tumor progression and metastasis in cholangiocarcinoma and serves as a prognostic biomarker.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholangiocarcinoma (CHOL) is a highly fatal malignancy originating from the bile ducts, with most patients diagnosed at an advanced stage, limiting treatment options. This study explores the role of Muscleblind-like 3 (MBNL3), a conserved RNA-binding protein, in CHOL progression, particularly its involvement in metastasis and immune microenvironment regulation. Using data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO), we investigated MBNL3 expression and its correlation with patient prognosis. High MBNL3 expression was associated with significantly better overall survival (OS), progression-free survival (PFS), disease-specific survival (DSS), and disease-free interval (DFI) in CHOL patients. Functional analysis revealed that MBNL3 modulates epithelial-mesenchymal transition (EMT) and interacts with critical pathways, including focal adhesion, collagen signaling, and TNF signaling. Additionally, MBNL3 influences immune cell infiltration, with high expression linked to increased macrophage and Th17 cell presence, suggesting potential roles in immune response modulation. Experimental validation confirmed that silencing MBNL3 promotes EMT, enhances tumor cell migration and invasion, and increases metastasis in vivo. Furthermore, genetic analyses highlighted the impact of MBNL3 mutations and methylation on CHOL progression, identifying potential targets for immunotherapy. This is the first study to investigate MBNL3's role in CHOL, positioning it as a prognostic biomarker and a promising therapeutic target for improving outcomes in CHOL patients. Further research is needed to elucidate the molecular mechanisms underlying MBNL3's regulation of tumor metastasis and the immune microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.